Market Overview

38 Stocks Moving In Tuesday's Mid-Day Session

Share:

Gainers

  • Biocept, Inc. (NASDAQ: BIOC) shares rose 73.6 percent to $1.19 after the company entered a software license and laboratory data supply agreement with Prognos.
  • Marin Software Incorporated (NASDAQ: MRIN) shares climbed 37.8 percent to $3.94 after the company announced it has entered a revenue sharing agreement with Google. The company also raised Q4 guidance.
  • Navistar International Corporation (NYSE: NAV) rose 17.8 percent to $28.08 after the company reported better-than-expected results for its fourth quarter.
  • ReShape Lifesciences Inc. (NASDAQ: RSLS) gained 15.5 percent to $0.4750 after the company acquired Apollo Endosurgery's lap-band system.
  • Kodiak Sciences Inc. (NASDAQ: KOD) shares climbed 15.3 percent to $7.68.
  • CollPlant Holdings Ltd. (NASDAQ: CLGN) shares gained 14.2 percent to $4.98.
  • Materialise NV (NASDAQ: MTLS) shares climbed 12.9 percent to $17.82.
  • Limbach Holdings, Inc. (NASDAQ: LMB) gained 12.1 percent to $3.99.
  • The Meet Group, Inc. (NASDAQ: MEET) rose 11.3 percent to $3.7511. The Meet Group reported that annualized video revenue run-rate rose to $62 million in November, up from $55 million in October.
  • Tyme Technologies, Inc. (NASDAQ: TYME) gained 10.5 percent to $3.58.
  • NRC Group Holdings Corp. (NASDAQ: NRCG) climbed 9.4 percent to $9.31.
  • SMART Global Holdings, Inc. (NASDAQ: SGH) rose 9.2 percent to $30.65. SMART Global will replace XO Group in the S&P SmallCap 600 on Monday, December 24.
  • Tilray, Inc. (NASDAQ: TLRY) climbed 8.1 percent to $71.20 after the company announced a partnership with German pharmaceutical company Sandoz to distribute non-smokable medical cannabis products.
  • Boot Barn Holdings, Inc. (NYSE: BOOT) climbed 7.6 percent to $17.12.
  • Scientific Games Corporation (NASDAQ: SGMS) shares rose 7.5 percent to $17.05.
  • Cellect Biotechnology Ltd. (NASDAQ: APOP) shares gained 6.8 percent to $2.67.
  • HealthEquity, Inc. (NASDAQ: HQY) gained 6.6 percent to $63.59. Cantor Fitzgerald upgraded Healthequity from Neutral to Overweight.
  • HEICO Corporation (NYSE: HEI) climbed 5.9 percent to $82.44 after the company beat Q4 EPS and sales estimates.
  • FibroGen, Inc. (NASDAQ: FGEN) rose 5.6 percent to $41.17 after the company said its China unit has received marketing authorization from the National Medical Products Administration for Roxadustat, a hypoxia-inducible factor propyl hydroxylase inhibitor for treating patients with anemia caused by chronic kidney disease, who are dialysis dependent.
  • NCR Corporation (NYSE: NCR) shares gained 5.3 percent to $23.90. RBC Capital upgraded NCR from Outperform to Top Pick.
  • Puma Biotechnology, Inc. (NASDAQ: PBYI) rose 5 percent to $22.48 after the company reported favorable results from its Phase III NALA trial of Neratinib in breast cancer patients.

 

Check out these big penny stock gainers and losers

Losers

  • Nemaura Medical Inc. (NASDAQ: NMRD) shares tumbled 39.2 percent to $0.8450 after the company priced its $2.5 million share common stock offering at $1.02 per share.
  • Champions Oncology, Inc. (NASDAQ: CSBR) shares declined 18.4 percent to $7.79. Champions Oncology reported Q2 revenues of $6.7 million, up 28.6 percent year-over-year, and non-GAAP EPS of 3 cents compared to break-even results a year ago.
  • Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) dipped 17.4 percent to $2.33.
  • OptimizeRx Corporation (NASDAQ: OPRX) dipped 16.8 percent to $9.65 after the company priced its offering of approximately 2.1 million shares at $10 per share.
  • Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) shares fell 16.3 percent to $7.54.
  • Cancer Genetics, Inc. (NASDAQ: CGIX) dipped 15.9 percent to $0.2800 on continued weakness after the company on Monday announced it has terminated its proposed merger with NovellusDx.
  • Motus GI Holdings, Inc. (NASDAQ: MOTS) shares dropped 15.8 percent to $2.6942 after reporting a proposed 5 million share follow-on offering of common stock.
  • Rent-A-Center, Inc. (NASDAQ: RCII) fell 15.6 percent to $12.19 after terminating its merger agreement with Vintage Capital.
  • Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) shares dropped 14.8 percent to $2.0450 after the company reported positive interim Phase 2 trials of its first-gen oral factor D inhibitor ACH-4471, as well as pharmacokinetics and potency data for its next-gen factor D inhibitors ACH-5228 and ACH-5548.
  • Evofem Biosciences, Inc. (NASDAQ: EVFM) fell 14.3 percent to $3.4700 after climbing 15.71 percent on Monday.
  • NF Energy Saving Corporation (NASDAQ: NFEC) dropped 12.4 percent to $9.35.
  • Worthington Industries, Inc. (NYSE: WOR) shares fell 10.9 percent to $32.67 after the company posted downbeat Q2 results.
  • Integrated Media Technology Limited (NASDAQ: IMTE) dropped 9.1 percent to $4.41.
  • Eyenovia, Inc. (NASDAQ: EYEN) shares tumbled 8.7 percent to $2.83.
  • RiceBran Technologies (NASDAQ: RIBT) dipped 7.4 percent to $3.11.
  • Washington Prime Group Inc. (NYSE: WPG) fell 7.2 percent to $5.36 after dropping 6.18 percent on Monday. Goldman Sachs downgraded Washington Prime Group from Neutral to Sell.
  • Comstock Resources, Inc. (NYSE: CRK) dropped 6.6 percent to $4.68.

Posted-In: LosersNews Movers & Shakers Intraday Update Markets Movers Trading Ideas General

 

Related Articles (ACHN + APOP)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Nasdaq 100 Inclusion A 'Small Near-Term Positive' For AMD, RBC Says

Despite Earnings Beat, Expect More Short-Term Downside In Oracle